Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Go back to Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)| LOGICVISION (NASDAQ: LGVN) | Delayed: 0.78 +0.01 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.77 | 52 Week High | $1.62 | |||
| Open | $0.78 | 52 Week Low | $0.35 | |||
| Day High | $0.82 | P/E | N/A | |||
| Day Low | $0.78 | EPS | $-0.17 | |||
| Volume | 135,362 | |||||
| (NASDAQ: LGVNR) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $ | |||
| Open | $2.45 | 52 Week Low | $ | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $ | |||
| Volume | 23,525,480 | |||||
